The triple-agonist peptide retatrutide achieved unprecedented weight loss in the TRIUMPH-4 trial while also providing substantial relief from osteoarthritis knee pain.
Eli Lilly has released positive topline results from the TRIUMPH-4 Phase 3 clinical trial evaluating retatrutide in adults with obesity or overweight who also have knee osteoarthritis. Participants receiving the highest dose achieved an average weight loss of approximately 71 pounds, making retatrutide one of the most potent anti-obesity agents ever tested in a large-scale trial.
What sets retatrutide apart from existing medications is its triple-agonist mechanism. While tirzepatide targets two receptors (GIP and GLP-1), retatrutide adds a third target — the glucagon receptor — which is believed to contribute to its enhanced fat-burning effects. In earlier Phase 2 data published in the New England Journal of Medicine, retatrutide demonstrated up to 24.2 percent body weight reduction at 48 weeks.
Beyond weight loss, the TRIUMPH-4 trial also showed meaningful improvements in osteoarthritis pain scores, suggesting that the substantial reduction in body weight translates to functional benefits for patients with joint disease. Seven additional Phase 3 readouts are expected throughout 2026, and a potential FDA submission could follow in 2026 or 2027.
Source: Eli Lilly Investor Relations
Share this article
The Peptide Wizard
High-quality research peptides for lab use. Third-party tested with certificate of analysis available on every product.
Visit The Peptide WizardSponsored content. ThePBrief receives compensation. For research purposes only.